[Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].
The efficacy of a retard preparation of allopurinol is verified by biochemical, pharmacological and clinical investigations. The action of a 300 mg allopurinol tablet, with normal release and absorption parameters, is based on the specific activity of oxypurinol, a metabolite which is formed from allopurinol according to a biotransformation process. The inhibitory action of oxypurinol on xanthine oxidase amounts to only 1/5th of that of allopurinol. On the other hand allopurinol shows an extremely short half life, so that a slow-release preparation of allopurinol seems the better way of administration to get adequate uricostatic efficacy by a single dose over a 24-hour period.
D000493:Allopurinol / Q000097:blood / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D014527:Uric Acid / Q000097:blood*
D003692:Delayed-Action Preparations; D014527:Uric Acid; D000493:Allopurinol
Zur Frage der therapeutischen Wirksamkeit von Allopurinol in retardform bei Gicht und Hyperurikämie.